Drug delivery and therapeutic impact of extended-release acetylsalicylic acid.

Journal Article (Review)

Current treatment guidelines recommend once-daily, low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention of cardiovascular events. However, the anti-thrombotic benefits of traditional ASA formulations may not extend over a 24-h period, especially in patients at high risk for a recurrent cardiovascular event. A next-generation, extended-release ASA formulation (ER-ASA) has been developed to provide 24-h anti-thrombotic coverage with once-daily dosing. The pharmacokinetics of ER-ASA indicates slower absorption and prolonged ASA release versus immediate-release ASA, with a favorable safety profile. ER-ASA minimizes systemic ASA absorption and provides sustained antiplatelet effects over a 24-h period.

Full Text

Duke Authors

Cited Authors

  • Bliden, KP; Patrick, J; Pennell, AT; Tantry, US; Gurbel, PA

Published Date

  • January 2016

Published In

Volume / Issue

  • 12 / 1

Start / End Page

  • 45 - 58

PubMed ID

  • 26356085

Electronic International Standard Serial Number (EISSN)

  • 1744-8298

International Standard Serial Number (ISSN)

  • 1479-6678

Digital Object Identifier (DOI)

  • 10.2217/fca.15.60

Language

  • eng